[go: up one dir, main page]

MX2018014028A - Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet). - Google Patents

Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).

Info

Publication number
MX2018014028A
MX2018014028A MX2018014028A MX2018014028A MX2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A MX 2018014028 A MX2018014028 A MX 2018014028A
Authority
MX
Mexico
Prior art keywords
imaging
immunomodulators
pet
millamolecules
labeled
Prior art date
Application number
MX2018014028A
Other languages
English (en)
Inventor
j donnelly David
M Boy Kenneth
Zhang Yunhui
Kim Joonyoung
Pena Adrienne
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2018014028A publication Critical patent/MX2018014028A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03Computed tomography [CT]
    • A61B6/037Emission tomography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12Arrangements for detecting or locating foreign bodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se refiere a la síntesis y el uso de millamoléculas marcadas con 18F para obtener imágenes de varios procesos dentro del cuerpo, para detectar la localización de moléculas asociadas con patología de la enfermedad, y para monitorear la progresión de la enfermedad.
MX2018014028A 2016-05-19 2017-05-17 Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet). MX2018014028A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (1)

Publication Number Publication Date
MX2018014028A true MX2018014028A (es) 2019-04-04

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014028A MX2018014028A (es) 2016-05-19 2017-05-17 Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).

Country Status (25)

Country Link
US (2) US11103605B2 (es)
EP (2) EP3827849A1 (es)
JP (1) JP6953444B2 (es)
KR (1) KR102378288B1 (es)
CN (1) CN109414514B (es)
AU (1) AU2017268291B2 (es)
BR (1) BR112018073642A2 (es)
CA (1) CA3024844A1 (es)
CY (1) CY1124241T1 (es)
DK (1) DK3458111T3 (es)
EA (1) EA038019B1 (es)
ES (1) ES2864091T3 (es)
HR (1) HRP20210644T8 (es)
HU (1) HUE054306T2 (es)
IL (1) IL262962B (es)
LT (1) LT3458111T (es)
MA (1) MA53402A (es)
MX (1) MX2018014028A (es)
PL (1) PL3458111T3 (es)
PT (1) PT3458111T (es)
RS (1) RS61742B1 (es)
SG (1) SG11201810177VA (es)
SI (1) SI3458111T1 (es)
SM (1) SMT202100238T1 (es)
WO (1) WO2017201111A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
JP7105235B2 (ja) 2016-12-01 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫petイメージングのための放射性標識された抗pd-l1抗体
EP3558395A4 (en) 2016-12-23 2020-08-12 The Johns Hopkins University IMAGING OF TUMOR CELLS AND IMMUNE CELLS BASED ON PD-L1 EXPRESSION
IL268667B2 (en) 2017-02-10 2024-12-01 Regeneron Pharma Radiolabeled antibodies against LAG3 for immuno-PET imaging
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
MX2020000916A (es) 2017-07-24 2020-09-10 Regeneron Pharma Anticuerpos anti-cd8 y usos de estos.
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
KR20220122752A (ko) 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 면역조정제
CN115485288A (zh) * 2020-03-16 2022-12-16 百时美施贵宝公司 免疫调节剂
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
JP2026500238A (ja) * 2022-12-12 2026-01-06 メルク・シャープ・アンド・ドーム・エルエルシー グランザイムbのpet造影剤としての環状ペプチド

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
ES2297862T3 (es) 1996-07-12 2008-05-01 Immunomedics, Inc. Analogos de peptidos que se unen a radiometales.
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
DE69837095T2 (de) 1997-09-03 2007-11-22 Immunomedics, Inc. Fluorierung von proteinen und peptiden für positronemissionstomographie
EP3012265B1 (en) 2007-03-26 2017-06-28 The University of Tokyo Process for synthesizing cyclic peptide compound
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
US10195578B2 (en) 2010-12-03 2019-02-05 The University Of Tokyo Peptide library production method, peptide library, and screening method
CN103732238A (zh) 2011-06-08 2014-04-16 奥瑞基尼探索技术有限公司 用于免疫调节的治疗性化合物
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
US9422339B2 (en) 2012-03-29 2016-08-23 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo pH依存的に標的分子に結合するペプチドのスクリーニング方法
CN104603145B (zh) 2012-06-06 2018-05-18 波利弗尔股份公司 β-发夹肽模拟物
KR20230070054A (ko) 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EA201891818A3 (ru) 2013-09-06 2019-03-29 Ауриген Дискавери Текнолоджиз Лимитед Способ получения соединений, используемых при получении циклических пептидомиметических соединений
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
EA034496B1 (ru) 2014-09-11 2020-02-13 Бристол-Майерс Сквибб Компани Макроциклические ингибиторы белок/белковых взаимодействий pd-1/pd-l1 и cd80(b7-1)/pd-l1
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
MX385081B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Métodos y composiciones para radioetiquetado con 18f de productos biológicos.
AU2015353573B2 (en) * 2014-11-25 2020-09-03 Bristol-Myers Squibb Company Novel PD-L1 binding polypeptides for imaging
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2018085750A2 (en) 2016-11-07 2018-05-11 Bristol-Myers Squibb Company Immunomodulators
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
EP3692053A1 (en) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulators

Also Published As

Publication number Publication date
SG11201810177VA (en) 2018-12-28
AU2017268291A1 (en) 2019-01-17
MA53402A (fr) 2021-06-02
DK3458111T3 (da) 2021-04-26
AU2017268291B2 (en) 2022-09-29
EA201892635A1 (ru) 2019-04-30
US11103605B2 (en) 2021-08-31
RS61742B1 (sr) 2021-05-31
IL262962A (en) 2018-12-31
EP3827849A1 (en) 2021-06-02
IL262962B (en) 2020-04-30
HRP20210644T8 (hr) 2021-06-25
BR112018073642A2 (pt) 2019-02-26
JP6953444B2 (ja) 2021-10-27
LT3458111T (lt) 2021-05-25
SI3458111T1 (sl) 2021-07-30
SMT202100238T1 (it) 2021-05-07
KR102378288B1 (ko) 2022-03-23
EA038019B1 (ru) 2021-06-23
JP2019520328A (ja) 2019-07-18
ES2864091T3 (es) 2021-10-13
US20190117801A1 (en) 2019-04-25
CN109414514A (zh) 2019-03-01
HRP20210644T1 (hr) 2021-05-28
PT3458111T (pt) 2021-04-09
EP3458111A1 (en) 2019-03-27
HUE054306T2 (hu) 2021-08-30
CN109414514B (zh) 2022-03-11
EP3458111B1 (en) 2021-03-03
US20210386876A1 (en) 2021-12-16
WO2017201111A1 (en) 2017-11-23
KR20190009330A (ko) 2019-01-28
PL3458111T3 (pl) 2021-06-28
CA3024844A1 (en) 2017-11-23
CY1124241T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
MX2018014028A (es) Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet).
WO2016086036A3 (en) Methods and compositions for 18f-radiolabeling of biologics
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
IL256175A (en) Using exosomes to treat the disease
EP3346917A4 (en) ULTRADICHTES ELECTRODE BASED BRAIN IMAGING SYSTEM
MX2021014367A (es) Anticuerpos tau humanizados en enfermedad de alzheimer.
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
IL256685B (en) An isolated tau-binding antibody and its use in the treatment and diagnosis of tauopathy
IL255919A (en) Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror gamma and the treatment of disease
MX383202B (es) Sondas para la proyección de imagen de la proteína huntingtina.
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
ZA201804079B (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease
DK3463351T3 (da) Behandling til parkinsons sygdom
BR112017011543A2 (pt) peptídeos cíclicos derivados de cd44v6 para o tratamento de cânceres e doenças relacionadas à angiogênese
EP3431595A4 (en) MONITORING AND DIAGNOSIS FOR IMMUNOTHERAPY AND DESIGN FOR THERAPEUTICS
PL3297625T3 (pl) Związek do profilaktyki lub leczenia nefropatii cukrzycowej lub cukrzycowej choroby nerek
EP3555319C0 (en) DIAGNOSIS OF PARKINSON'S DISEASE BASED ON REDUCED GLOBAL TRANSLATION
IL266778A (en) Combined discrimination for the differential diagnosis of Alzheimer's disease
PL3449009T3 (pl) Biomarkery mikroRNA we krwi do diagnozowania choroby Alzheimera
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
GB201601544D0 (en) Kidney disease diagnostic
NZ732381A (en) Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
PL3148588T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona
EP3373014A4 (en) DIAGNOSTIC MARKER FOR CONCORRARY DISEASE